Macomics is focused on leveraging its advanced understanding of macrophage biology to develop innovative therapeutics aimed at modulating macrophage activity in various diseases, particularly where existing treatments are inadequate. The company emphasizes the significance of macrophages and microglia in the pathology of diseases such as specific tumor subtypes, neurological disorders, and fibrotic and inflammatory conditions. By utilizing insights from human genetic and clinical evidence, Macomics aims to create new therapeutic strategies that can effectively alter disease progression through targeted macrophage interventions.

Central to Macomics' approach is its proprietary ENIGMAC™ discovery platform, which facilitates the translation of disease-specific macrophage biology into actionable therapeutic targets. This platform integrates a comprehensive Macrophage Atlas, which is a vast collection of gene expression data from patient and normal tissues, with advanced cellular models that allow for high-throughput drug discovery. The ENIGMAC™ platform enables precise gene editing of macrophages, supporting the identification and validation of new drug targets. Through this innovative technology, Macomics is advancing a diverse portfolio of antibody and small molecule programs, with a commitment to improving patient outcomes in diseases where macrophages play a critical role.

United Kingdom

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

Macomics

Company Details